Patents by Inventor Khalid Shah

Khalid Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE
    Publication number: 20240010621
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Application
    Filed: June 29, 2023
    Publication date: January 11, 2024
    Inventor: Khalid Shah
  • CRYSTALLINE SOLID FORMS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE
    Publication number: 20230382867
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 30, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Liquid Dosage Forms to Treat Cancer
    Publication number: 20230301978
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Application
    Filed: October 28, 2022
    Publication date: September 28, 2023
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
    Patent number: 11760726
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
    Patent number: 11731941
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: August 22, 2023
    Inventor: Khalid Shah
  • Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
    Patent number: 11724986
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 15, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Processes for the Preparation of a Kinase Inhibitor
    Publication number: 20230192619
    Abstract: The present invention relates to processes for the synthetic preparation of c-Met inhibitors of Formula I, or pharmaceutically acceptable salts thereof. The present invention further relates to processes for the synthetic preparation of the c-Met inhibitor, Compound 1, or a pharmaceutically acceptable salt thereof. The present invention also relates to processes for the synthetic preparation of Compound 1.hemifumarate. The invention further relates to large scale processes for the synthetic preparation of the c-Met inhibitor, Compound 1 and Compound 1.hemifumarate.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 22, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Yong Wang, Wei Xu
  • Salt Forms of a Kinase Inhibitor
    Publication number: 20230052703
    Abstract: The present invention relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid crystalline salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: February 16, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Crystalline Forms and Salt Forms of a Kinase Inhibitor
    Publication number: 20230029213
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 26, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • C-Met Modulator Pharmaceutical Compositions
    Publication number: 20220370436
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: July 20, 2022
    Publication date: November 24, 2022
    Inventors: Jo Ann Wilson, Khalid Shah
  • Liquid dosage forms to treat cancer
    Patent number: 11504362
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 22, 2022
    Assignee: Exelixis, Inc.
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
    Publication number: 20220175757
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Inventors: Jo Ann Wilson, Khalid Shah
  • CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE
    Publication number: 20220162166
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Application
    Filed: February 9, 2022
    Publication date: May 26, 2022
    Inventor: Khalid Shah
  • Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
    Patent number: 11298349
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: April 12, 2022
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • C-Met Modulator Pharmaceutical Compositions
    Publication number: 20220087999
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Jo Ann Wilson, Khalid Shah
  • Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
    Patent number: 11279675
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Grant
    Filed: May 26, 2018
    Date of Patent: March 22, 2022
    Assignee: Exelixis, Inc.
    Inventor: Khalid Shah
  • C-Met Modulator Pharmaceutical Compositions
    Publication number: 20220031688
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 3, 2022
    Inventors: Jo Ann Wilson, Khalid Shah
  • COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES
    Publication number: 20220023338
    Abstract: Described herein are methods and compositions for treating cancer. Various embodiments use engineered autologous or syngeneic cancer cells that home to tumors in vivo and deliver therapeutic polypeptides. Various embodiments further promote an anti-tumor immune response that can assist in treating existing tumors and provide protection against recurrent cancer.
    Type: Application
    Filed: May 15, 2019
    Publication date: January 27, 2022
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Khalid SHAH
  • Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
    Publication number: 20220023284
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Jo Ann Wilson, Khalid Shah
  • C-Met Modulator Pharmaceutical Compositions
    Publication number: 20210379050
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 9, 2021
    Inventors: Jo Ann Wilson, Khalid Shah